Stamford, United States
Cara Therapeutics, founded in 2004 and headquartered in the United States, is a biopharmaceutical innovator committed to enhancing the treatment of pruritus through novel therapeutic approaches. With its slogan, "Transforming the way pruritus is treated to bring quality to the lives of those who suffer," the company is making significant strides in addressing this chronic condition.
At the forefront of its development pipeline is the oral formulation of difelikefalin, which targets kappa opioid receptors to alleviate pruritus, particularly for patients with notalgia paresthetica, an often-overlooked neuropathy. Currently in a Phase 2/3 clinical trial, results are anticipated in Q3 2024. Meanwhile, their IV formulation is widely recognized, with approvals across the U.S., EU, and beyond. This version is already enhancing lives of those with chronic kidney disease undergoing hemodialysis.
In November 2023, Cara Therapeutics secured a $40.00M post-IPO debt investment from HealthCare Royalty Partners, reinforcing its financial stability and capacity to advance its groundbreaking therapeutic initiatives.
